OncoMatch/Clinical Trials/NCT03467360
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
Is NCT03467360 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including acetazolamide in combination with platinum and etoposide-based radiochemotherapy and acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC for small cell lung cancer.
Treatment: acetazolamide in combination with platinum and etoposide-based radiochemotherapy · acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC — The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines, 3. The observed synergy between irradiation and inhibition of carbonic anhydrases, 4. Potential anti-tumor immune effect caused by decreased extracellular acidity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage LOCALIZED, EXTENSIVE
Excluded: Stage IV
histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy with platinum and etoposide (platinum, etoposide) — localized SCLC sub-group
Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group)
Must have received: chemoimmunotherapy with platinum salts, etoposide and immunotherapy (platinum salts, etoposide, atezolizumab, durvalumab) — extensive SCLC sub-group
Patient who received 4 cycles of chemoimmunotherapy with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as the first treatment (extensive SCLC sub-group)
Cannot have received: thoracic irradiation
History of thoracic irradiation or near / in the thoracic irradiation field
Lab requirements
Cardiac function
congestive heart failure unbalanced (ejection fraction <30%, clinical signs)
Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction <30%, clinical signs), severe respiratory failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify